Stroke

The 510(k) clearance was supported by a 3-study, 159-patient registrational program showing a 45.5% increase in response rate vs physical therapy alone, and includes Medicare coverage at launch.

Catch up on any of the neurology headlines you may have missed in May 2026, compiled into 1 place by the NeurologyLive® team.

Christina Xia, MD, a stroke specialist at Cleveland Clinic, reviewed recent advances in stroke rehabilitation, including neuromodulation and emerging approaches aimed at improving long-term recovery after stroke.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute discussed how structured cardiovascular rehabilitation may improve recovery outcomes, reduce mortality, and influence future Medicare coverage for poststroke care.

Sara Cuccurullo, MD, chair, vice president, and medical director, Hackensack Meridian JFK Johnson Rehabilitation Institute, discussed emerging evidence supporting structured cardiovascular rehabilitation after stroke and ongoing efforts to expand access through potential Medicare policy changes.

FDA priority review of asundexian marks a key regulatory milestone for factor XIa inhibition in secondary stroke prevention following positive phase 3 OCEANIC-STROKE results.

From exercise and lifestyle medicine to neuromodulation and vagus nerve stimulation, Andrew Abdou, DO, discusses emerging approaches that may help stroke patients continue recovery beyond traditional timelines.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 15, 2026.

In honor of Stroke Awareness Month, neurologist Firas Bounni, MD, discussed how advanced neuroimaging can guide thrombectomy decision-making beyond standard treatment windows.

Kristine Yaffe, MD, distinguished professor at UCSF and SEQUINS Hall of Fame honoree, discusses dementia prevention, modifiable risk factors, and ongoing disparities in brain health and cognitive aging.

As a 2026 SEQUINS Hall of Fame honoree, James Galvin, MD, MPH, reflected on advancing equitable dementia care, culturally relevant cognitive assessment, and improving brain health outcomes across diverse communities.

As a 2026 SEQUINS Hall of Fame honoree, George Howard, DrPH, commented on decades of stroke disparities research, the impact of the REGARDS study, and why future efforts must focus more directly on upstream risk factors.

As a 2026 SEQUINS Hall of Fame honoree, Gretchen L. Birbeck, MD, MPH, reflected on her decades-long work advancing equity in global neurologic care and improving epilepsy outcomes in resource-limited settings.

As a 2026 SEQUINS Hall of Fame honoree, Edwin Trevathan, MD, MPH, reflects on global pediatric neurology, community-based care delivery, and the ongoing effort to reduce neurologic health inequities worldwide.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Stroke Awareness Month!

BIOX-101 showed early signals of reduced edema growth and improved functional outcomes in a phase 2a intracerebral hemorrhage trial, with a favorable safety profile, supporting advancement into a planned adaptive phase 2b/3 study.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 8, 2026.

Neurava secured a $4M NIH grant to develop and validate an AI-driven wearable platform for SUDEP risk prediction and real-time monitoring, aiming to improve clinical decision-making and early intervention in epilepsy care.

GLP-1 receptor agonists show growing relevance in neurology, with strongest evidence in stroke prevention and obstructive sleep apnea and emerging signals in idiopathic intracranial hypertension and migraine.

Here's some of what is coming soon to NeurologyLive® this week.

GMRx2 reduced recurrent stroke risk by 39% in patients with prior intracerebral hemorrhage in the phase 3 TRIDENT trial, supporting single-pill intensive blood pressure control as a promising secondary prevention strategy.

Here's some of what is coming soon to NeurologyLive® this week.

FDA issues complete response letter for GTx-104 in aneurysmal subarachnoid hemorrhage, citing manufacturing and nonclinical concerns despite positive phase 3 efficacy and safety data.

Edith Graham, MD, assistant professor of neurology at Northwestern Feinberg School of Medicine, discussed diagnostic challenges and induction therapy outcomes in primary CNS vasculitis.

Here's some of what is coming soon to NeurologyLive® this week.